A Phase II Study Demonstrates No Feasibility of Adjuvant Treatment with Six Cycles of S-1 and Oxaliplatin in Resectable Esophageal Adenocarcinoma, with ERCC1 as Biomarker for Response to SOX

SIMPLE SUMMARY: Neoadjuvant chemoradiotherapy followed by surgery is currently standard of care in esophageal adenocarcinoma. However, prognosis remains dismal. The aim of our study was to assess the feasibility of administering six cycles of adjuvant S-1 and oxaliplatin following neoadjuvant chemor...

Descripción completa

Detalles Bibliográficos
Autores principales: Stroes, Charlotte I., Schokker, Sandor, Molenaar, Remco J., Mathôt, Ron A. A., Bijlsma, Maarten F., van der Woude, Stephanie O., Belo Pereira, João P., Hooijer, Gerrit K. J., Verhoeven, Rob H. A., Cats, Annemieke, Grootscholten, Cecile, van Sandick, Johanna W., Creemers, Geert-Jan, Nieuwenhuijzen, Grard A. P., Haj Mohammad, Nadia, Ruurda, Jelle P., Meijer, Sybren L., Hulshof, Maarten C. C. M., van Berge Henegouwen, Mark I., van Laarhoven, Hanneke W. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7922275/
https://www.ncbi.nlm.nih.gov/pubmed/33671266
http://dx.doi.org/10.3390/cancers13040839

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7922275/
https://www.ncbi.nlm.nih.gov/pubmed/33671266
http://dx.doi.org/10.3390/cancers13040839

Ejemplares similares